WASHINGTON (Reuters) - The World Health Organization asked pharmaceutical companies on Thursday to end the marketing and sale of "single-drug" artemisinin malaria medicines, in order to prevent malaria parasites from developing resistance to the drug.
The use of single-drug artemisinin treatment, or "monotherapy," hastens development of resistance by weakening but not killing the parasite, WHO said in new malaria treatment guidelines.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
